Share on StockTwits

Eli Lilly and (NYSE:LLY) saw a large increase in short interest in the month of July. As of July 31st, there was short interest totalling 22,619,054 shares, an increase of 18.1% from the July 15th total of 19,160,146 shares, AR Network reports. Based on an average daily volume of 4,127,172 shares, the days-to-cover ratio is presently 5.5 days. Currently, 2.3% of the shares of the company are sold short.

Several analysts have recently commented on the stock. Analysts at Jefferies Group cut their price target on shares of Eli Lilly and from $65.00 to $61.00 in a research note on Monday. They now have a “hold” rating on the stock. Separately, analysts at S&P Equity Research initiated coverage on shares of Eli Lilly and in a research note on Friday, August 1st. They set a “buy” rating on the stock. Finally, analysts at Morgan Stanley raised their price target on shares of Eli Lilly and from $48.00 to $60.00 in a research note on Friday, August 1st. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $63.86.

Eli Lilly and (NYSE:LLY) opened at 61.19 on Friday. Eli Lilly and has a 52 week low of $47.53 and a 52 week high of $65.70. The stock’s 50-day moving average is $62.38 and its 200-day moving average is $59.35. The company has a market cap of $65.577 billion and a price-to-earnings ratio of 19.24.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Thursday, July 24th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.03. The company had revenue of $4.94 billion for the quarter, compared to the consensus estimate of $4.88 billion. During the same quarter in the previous year, the company posted $1.16 earnings per share. The company’s revenue for the quarter was down 16.8% on a year-over-year basis. Analysts expect that Eli Lilly and will post $2.78 EPS for the current fiscal year.

Eli Lilly and Company, discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.